---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-068745"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T14:42:27.400848+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INmune Bio Q3 net loss $7.7M; FDA clinical hold on XPro AD trials ongoing

## Summary
- Net loss Q3 2022 ~$7.7M vs $9.5M Q3 2021; R&D $5.2M, G&A $2.4M.
- Cash & equivalents ~$57.4M at Sept 30, 2022; ~17.9M shares outstanding.
- FDA clinical hold on XPro1595 AD trials; company addressed CMC query; discussions ongoing.
- INKmune shows positive solid tumor data; 2nd UK site Nov 2022; pre-IND with FDA for solid tumor.
- Upcoming: XPro Phase 2 AD/TRD after hold lifted; INKmune solid tumor 1H 2023.

## SEC filing metadata
- accession: 0001213900-22-068745
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390022068745/0001213900-22-068745-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390022068745/ea167968-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-068745
- JSON: https://secwatch.observer/filing/0001213900-22-068745.json
- Plain text: https://secwatch.observer/filing/0001213900-22-068745.txt

## Key facts
- Earnings Releases
  Inmune Bio, Inc. reported the quarter ended September 30, 2022 results: net income approximately $7.7 million.
  - Period: the quarter ended September 30, 2022
  - Net income: approximately $7.7 million
  - Result: reported results
  source text: Net loss attributable to common stockholders for the quarter ended September 30, 2022 was approximately $7.7 million, compared to approximately $9.5 million for the quarter ended September 30, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390022068745/0001213900-22-068745-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.